Thus, targeting DKK1 in breast cancer could offer multiple therapeutic benefits from increasing anti-tumor immunity via unleashing NK cell suppression from the tumor microenvironment to targeting disseminated tumor cells and/or cancer stem cells. Here, DKK1 is linked to neoplasm.